Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Taxoids. Found 14 abstracts

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crino L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-33.   PMCID: PMC6075826
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Borghaei H, Brahmer J. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer [comment]. The New England journal of medicine. 2016 Feb 04;374(5):493-4.   PMCID: NA
Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug;39(4):340-5.   PMCID: PMC4177955
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015 Oct 22;373(17):1627-39.
Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs. 2015 Aug;26(7):785-92.   PMCID: 4484664
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20;32(12):1210-7.   PMCID: Pmc3986384
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J Thorac Oncol. 2008 Sep;3(9):1032-8.
Kruh GD. Ins and outs of taxanes.[comment]. Cancer Biology & Therapy. 2005 Sep;4(9):1030-2.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Taxoids

Taxoids drug therapy therapeutic use Antineoplastic Agents Aged Male Middle Aged Lung Neoplasms Female pathology Non-Small-Cell Lung Carcinoma adverse effects Antineoplastic Combined Chemotherapy Protocols Adult Survival Rate administration & dosage Disease-Free Survival Monoclonal Antibodies chemically induced blood 0 (Taxoids) Neoplasm Staging mortality Deoxycytidine analogs & derivatives methods Adenocarcinoma 0 (Antineoplastic Agents) Paclitaxel Squamous Cell Carcinoma therapy Kaplan-Meier Estimate Prostate-Specific Antigen Survival Analysis secondary Monoclonal Antibodies-Humanized ch [Chemistry] Camptothecin 80 and over Aged tu [Therapeutic Use] Androgen Antagonists dt [Drug Therapy] adverse effects Salvage Therapy Prostatic Neoplasms 25513-46-6 (Polyglutamic Acid) Double-Blind Method Organoplatinum Compounds Comparative Study Biological Transport 114977-28-5 (docetaxel) 103882-84-4 (gemcitabine) tu [Therapeutic Combination Drug Therapy me [Metabolism] Antineoplastic Antibiotics Practice Guidelines as Topic Organic Anion Transport Polypeptide C Antineoplastic Antimetabolites Human ad [Administration & Dosage] Cohort Studies Prognosis Thromboembolism Neoplasm Drug Resistance Phytogenic Antineoplastic Agents 7689-03-4 (Camptothecin) agonists North America Ribonucleotide Reductases Intravenous Infusions Ovarian Neoplasms Neutropenia pd [Pharmacology] Anticoagulants Phytogenic) 0 (Antineoplastic Agents immunology Diarrhea androgen deprivation Gonadotropin-Releasing Hormone 0 (polyglutamic acid-paclitaxel) Molecular Structure Sodium-Independent Organic Anion Transporters Sodium-Independent) 0 (Organic Anion Transporters metabolism 0 (Antineoplastic Combined Chemotherapy Protocols) docetaxel Non-US Gov't Support Small Cell Carcinoma Hematologic Diseases Immunosuppressive Agents Kallikreins CD274 Antigens Nitriles Drug Dose-Response Relationship Maximum Tolerated Dose Cetuximab epidemiology Immunotherapy Risk Factors 33419-42-0 (Etoposide) CA-19-9 Antigen high risk Multivariate Analysis 33069-62-4 (Paclitaxel) Cisplatin Tosyl Compounds aa [Analogs & Derivatives] Adjuvant Chemoradiotherapy Local Neoplasm Recurrence Polyglutamic Acid Clinical Trials cy [Cytology] Hepatocytes Proportional Hazards Models Pancreatic Neoplasms Antineoplastic) 0 (Antimetabolites ai [Antagonists & Inhibitors] Conformal Radiotherapy pharmacokinetics Epothilones Cell Membrane radiation Etoposide Recurrence Type I DNA Topoisomerases 15663-27-1 (Cisplatin) antagonists & inhibitors 100286-90-6 (irinotecan) Vindesine 0 (Enzyme Inhibitors) Use] Adjuvant Radiotherapy Neoplasm Grading Type I) EC 5-99-1-2 (DNA Topoisomerases Logistic Models Enzyme Inhibitors Gastrointestinal Diseases Prostatectomy prevention & control 951-77-9 (Deoxycytidine) Anilides postprostatectomy Response Evaluation Criteria in Solid Tumors Peripheral Nervous System Diseases Young Adult chemotherapy Follow-Up Studies Biological Models
Last updated on Saturday, July 04, 2020